NCT06665568View on ClinicalTrials.gov

Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Depressive Symptoms Mild to Moderate in SeverityAnxietyQuality of Life (QOL)Caregiver BurdenSleep Quality
Interventions
DRUG

Intranasal ketamine hydrochloride

Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)

Trial Locations (1)

8091

University Hospital Zurich, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER